trial · primary record
Cyclophosphamide
Angioimmunoblastic T-cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 170 |
| Primary completion | 2027-05-19 |
| Primary endpoint | Complete remission (CR) rate |
| Registry ID | NCT04803201 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:30.152Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04803201
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cyclophosphamide · approval
- Cyclophosphamide · compound